Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2198
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
Minocycline Hydrochloride (Capsule)
|
| dailymed-instance:dosage |
Adults:
|
| dailymed-instance:clinicalP... |
Microbiology:<br/>Susceptibility Tests: A report of "Susceptible" indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected. Reports from the laboratory providing results of the standard single-disk susceptibility test with a 30 mcg tetracycline or minocycline disk should be interpreted according to the following criteria: For testing Streptococcus pneumoniae: Interpretation should be as stated above for results using dilution techniques. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for tetracycline.
|
| dailymed-instance:activeIng... | |
| dailymed-instance:contraind... |
This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines or to any of the components of the product formulation.
|
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... |
dailymed-ingredient:Black_Iron_Oxide,
dailymed-ingredient:Butyl_Alcohol,
dailymed-ingredient:Corn_Starch,
dailymed-ingredient:D&C_Red_#33,
dailymed-ingredient:Dehydrated_Alcohol,
dailymed-ingredient:FD&C_Red_#3,
dailymed-ingredient:FD&C_Yellow_#6,
dailymed-ingredient:Gelatin,
dailymed-ingredient:Isopropyl_Alcohol,
dailymed-ingredient:Magnesium_Stearate,
dailymed-ingredient:Potassium_Hydroxide,
dailymed-ingredient:Propylene_Glycol,
dailymed-ingredient:Shellac,
dailymed-ingredient:Sodium_Lauryl_Sulfate,
dailymed-ingredient:Strong_Ammonia_Solution,
dailymed-ingredient:Titanium_Dioxide
|
| dailymed-instance:precautio... |
General:<br/>Information for Patients:<br/>Laboratory Tests:<br/>Drug Interactions:<br/>Drug/Laboratory Test Interactions: False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.<br/>Carcinogenesis, Mutagenesis, Impairment of Fertility: Dietary administration of minocycline in long term tumorigenicity studies in rats resulted in evidence of thyroid tumor production. Minocycline has also been found to produce thyroid hyperplasia in rats and dogs. In addition, there has been evidence of oncogenic activity in rats in studies with a related antibiotic, oxytetracycline (i.e., adrenal and pituitary tumors). Likewise, although mutagenicity studies of minocycline have not been conducted, positive results in in vitro mammalian cell assays (i.e., mouse lymphoma and Chinese hamster lung cells) have been reported for related antibiotics (tetracycline hydrochloride and oxytetracycline). Segment I (fertility and general reproduction) studies have provided evidence that minocycline impairs fertility in male rats.<br/>Pregnancy:<br/>Teratogenic Effects:<br/>Nonteratogenic Effects:<br/>Labor And Delivery: The effect of tetracyclines on labor and delivery is unknown.<br/>Nursing Mothers: Tetracyclines are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from the tetracyclines, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.<br/>Pediatric Use: Minocycline is not recommended for the use in children below 8 years of age unless the expected benefits of therapy outweigh the risks.<br/>Geriatric Use: Clinical studies of oral minocycline did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
|
| dailymed-instance:genericMe... |
Minocycline Hydrochloride
|
| dailymed-instance:fullName |
Minocycline Hydrochloride (Capsule)
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
Minocycline Hydrochloride
|